HC Wainwright Forecasts Mainz Biomed Q1 Earnings

Mainz Biomed (NASDAQ:MYNZ) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Mainz Biomed in a note issued to investors on Monday, November 25th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of ($0.07) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Mainz Biomed’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Mainz Biomed’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.23) EPS.

Mainz Biomed Stock Performance

Mainz Biomed stock opened at $0.23 on Tuesday. Mainz Biomed has a 1 year low of $0.19 and a 1 year high of $1.79. The firm’s 50 day moving average price is $0.26 and its two-hundred day moving average price is $0.39.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.